Revenue
2011
2012
2014
2018
2019
2020
2021
2022
ENDONOVO THERAPEUTICS, INC. (ENDV)
Price—Loading quote
Net income
2014
2016
2017
2018
2019
2020
2021
2022
Free cash flow
2014
2018
2019
Total cash / debt
CashTotal debt
2014
2016
2017
2018
2019
2020
2021
2022
Financial statements
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $135,355 | $73,105 | $165,796 | $310,164 | $83,263 | — | — | $24,192 | $30,581 | $45,544 | $51,199 |
| Gross profit | $125,365 | $58,120 | $100,427 | $216,779 | $70,333 | — | — | $8,707 | — | — | — |
| Research & development | — | $0 | $3,283 | $153,126 | $274,265 | $115,159 | $0 | — | — | — | — |
| Operating expenses | $3.4M | $2.3M | $3.0M | $4.0M | $4.2M | $4.6M | $5.4M | $2.2M | $1.8M | $141,068 | $129,185 |
| Operating income | −$3.3M | −$2.2M | −$2.9M | −$3.8M | −$4.2M | −$4.6M | −$5.4M | −$2.2M | −$1.7M | −$95,524 | −$77,986 |
| EBITDAderived | −$2.6M | −$1.6M | −$2.3M | −$3.2M | −$3.5M | −$4.6M | −$5.4M | −$2.2M | −$1.7M | −$94,545 | −$77,022 |
| Net income | −$18.5M | −$3.1M | −$395,584 | −$17.3M | −$6.4M | −$10.8M | −$5.3M | −$959,494 | −$1.9M | −$94,088 | −$69,400 |
| Basic EPSper diluted share | -$0.13 | -$0.05 | -$0.03 | -$24.83 | -$17.76 | -$0.04 | -$0.05 | -$0.03 | -$0.04 | -$0.02 | -$0.02 |
| Diluted EPSper diluted share | — | -$0.05 | -$0.03 | -$24.83 | -$17.76 | -$0.04 | -$0.05 | -$0.03 | -$0.04 | -$0.02 | -$0.02 |